With Its R&D On Track, GSK R&D Chair Slaoui Cites Individual Responsibility, Culture As Success Factors
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma did notably fewer deals in 2011, largely because of stringent criteria, reined in by a tight budget for R&D, but also because of its recent interest in external venture capital partners, some of which are not disclosed to the public.